AASTROM BIOSCIENCES INC, DEF 14A, 2000-10-03

AASTROM BIOSCIENCES INC
DEF 14A, 2000-10-03
PHARMACEUTICAL PREPARATIONS

Previous: PERCEPTRON INC/MI, PRE 14A, 2000-10-03

Next: SMITH BARNEY ADJUSTABLE RATE GOVERNMENT INCOME FUND, 497, 2000-10-03

<PAGE>

================================================================================

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934

Filed by the Registrant [X]

Filed by a Party other than the Registrant [_]

Check the appropriate box:

[_] Preliminary Proxy Statement

[X] Definitive Proxy Statement

[_] Definitive Additional Materials

[_] Soliciting Material Pursuant to Section 240.14a-11(c) or Section 240.14a-12

Aastrom Biosciences, Inc.
(Name of Registrant as Specified In Its Charter)

Payment of Filing Fee (Check the appropriate box):

[X] No fee required.

[_] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:
(2) Aggregate number of securities to which transaction applies:
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (Set forth the amount on which
filing fee is calculated and state how it was determined):
(4) Proposed maximum aggregate value of transaction:
(5) Total fee paid:

[_] Fee paid previously with preliminary materials.

[_] Check box if any part of the fee is offset as provided by Exchange
Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee
was paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.

(1) Amount previously paid:
(2) Form, Schedule or Registration Statement No.:
(3) Filing Party:
(4) Date Filed:

================================================================================
<PAGE>

[LOGO OF AASTROM BIOSCIENCES, INC.]

October 3, 2000

Dear Shareholder:

This year's annual meeting of shareholders will be held on November 15, 2000
at 9:00 a.m. local time, at the Holiday Inn North Campus, 3600 Plymouth Road,
Ann Arbor, Michigan 48105. You are cordially invited to attend.

The Notice of Annual Meeting of Shareholders and a Proxy Statement, which
describe the formal business to be conducted at the meeting, follow this
letter.

After reading the Proxy Statement, please promptly mark, sign, and return
the enclosed proxy in the prepaid envelope to assure that your shares will be
represented. Your shares cannot be voted unless you date, sign, and return the
enclosed proxy or attend the annual meeting in person. Regardless of the number
of shares you own, your careful consideration of, and vote on, the matters
before our shareholders are important.

A copy of Aastrom's 2000 Annual Report is also enclosed.

The Board of Directors and management look forward to seeing you at the
annual meeting.

Very truly yours,

/s/ R. Douglas Armstrong
_____________________________________
R. Douglas Armstrong
President and Chief Executive
Officer
<PAGE>

[LOGO OF AASTROM BIOSCIENCES, INC.]

AASTROM BIOSCIENCES, INC.
24 Frank Lloyd Wright Drive
Ann Arbor, MI 48105

NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
TO BE HELD NOVEMBER 15, 2000

Dear Shareholder:

You are invited to attend the Annual Meeting of the Shareholders of Aastrom
Biosciences, Inc. which will be held on November 15, 2000, at 9:00 a.m. at the
Holiday Inn North Campus, 3600 Plymouth Road, Ann Arbor, Michigan 48105 for the
following purposes:

1. To elect two Class III directors, each to hold office for a three-year
term and until their respective successors are elected and qualified.
Management has nominated the following persons for election at the
meeting: Joseph A. Taylor and R. Douglas Armstrong, Ph.D.

2. To consider and vote upon a proposal to amend the 1992 Incentive and
Non-Qualified Stock Option Plan to increase the maximum aggregate number
of shares reserved for issuance thereunder by 1,400,000.

3. To consider and vote upon a proposal to amend the 1996 Outside Directors
Stock Option Plan to (i) increase by 150,000 the maximum number of
shares of Aastrom's common stock that may be issued thereunder; and (ii)
to increase the size of the Initial Option Grant and Annual Option
granted after the date of the 2000 Annual Meeting of Shareholders from
5,000 to 10,000 shares.

4. To ratify the appointment of PricewaterhouseCoopers LLP as Aastrom's
independent public accountants for the fiscal year ending June 30, 2001.

5. To transact such other business as may properly come before the meeting.

Shareholders of record at the close of business on September 29, 2000 are
entitled to notice of, and to vote at, this meeting and any adjournments
thereof. For ten days prior to the meeting, a complete list of the shareholders
of record on September 29, 2000 will be available for examination by any
shareholder for any purpose relating to the meeting during ordinary business
hours at Aastrom.

By order of the Board of Directors,

/s/ Todd E. Simpson
_____________________________________
TODD E. SIMPSON
Secretary

Ann Arbor, Michigan
October 3, 2000

IMPORTANT: Please fill in, date, sign and promptly mail the enclosed proxy
card in the accompanying postpaid envelope to assure that your shares are
represented at the meeting. If you attend the meeting, you may choose to
vote in person even if you have previously sent in your proxy card.

<PAGE>

AASTROM BIOSCIENCES, INC.
24 Frank Lloyd Wright Drive
Ann Arbor, Michigan 48105

Proxy Statement for Annual Meeting of Shareholders

The accompanying proxy is solicited by the Board of Directors of Aastrom
Biosciences, Inc., a Michigan corporation (Aastrom), for use at the Annual
Meeting of Shareholders to be held November 15, 2000, or any adjournment
thereof, for the purposes set forth in the accompanying Notice of Annual
Meeting. The date of this Proxy Statement is September 29, 2000, the
approximate date on which this Proxy Statement and the accompanying form of
proxy were first sent or given to shareholders. Unless the context requires
otherwise, references to "we," "us," "our," and Aastrom refer to Aastrom
Biosciences, Inc.

GENERAL INFORMATION

Annual Report. An annual report for the fiscal year ended June 30, 2000, is
enclosed with this Proxy Statement.

Voting Securities. Only shareholders of record as of the close of business
on September 29, 2000, will be entitled to vote at the meeting and any
adjournment thereof. As of that date, there were 33,842,388 shares of common
stock, no par value, of Aastrom, issued and outstanding. Shareholders may vote
in person or by proxy. Each holder of shares of common stock is entitled to one
vote for each share of stock held on the proposals presented in this Proxy
Statement. Aastrom's bylaws provide that a majority of all of the shares of the
stock entitled to vote, whether present in person or represented by proxy,
shall constitute a quorum for the transaction of business at the meeting.

Solicitation of Proxies. The cost of soliciting proxies will be borne by
Aastrom. In addition, Aastrom will solicit shareholders by mail through its
regular employees, and will request banks and brokers, and other custodians,
nominees and fiduciaries, to solicit their customers who have stock of Aastrom
registered in the names of such persons and will reimburse them for their
reasonable, out-of-pocket costs. Aastrom may use the services of its officers,
directors, and others to solicit proxies, personally or by telephone, without
additional compensation.

Voting of Proxies. All valid proxies received prior to the meeting will be
voted. All shares represented by a proxy will be voted, and where a shareholder
specifies a choice with respect to any matter to be acted upon, the shares will
be voted in accordance with the specification so made. If no choice is
indicated on the proxy, the shares will be voted in favor of the election of
the nominees for director contained in this Proxy Statement, in favor of the
three other proposals specified in the Notice of the meeting, and in the
discretion of the proxy holders on any other matter that comes before the
meeting. A shareholder giving a proxy has the power to revoke his or her proxy,
at any time prior to the time it is voted, by delivery to the Secretary of
Aastrom of either a written instrument revoking the proxy or a duly executed
proxy with a later date, or by attending the meeting and voting in person.

Stock Ownership of Certain Beneficial Owners and Management. The following
table sets forth certain information, as of August 31, 2000, with respect to
the beneficial ownership of Aastrom's common stock by (i) all persons known by
Aastrom to be the beneficial owners of more than 5% of the outstanding common
stock of Aastrom, (ii) each director and director-nominee of Aastrom, (iii)
each executive officer of Aastrom named in the Summary Compensation Table, and
(iv) all executive officers and directors of Aastrom as a group.
<PAGE>

<TABLE>
<CAPTION>
Shares Owned(1)
---------------------
Number Percentage
Name and Address of Beneficial Owner(2) of Shares of Class(3)
--------------------------------------- --------- -----------
<S> <C> <C>
RGC International Investors, LDC(4).................................. 3,433,431 9.9%
c/o Rose Glen Capital Management, L.P.
3 Bala Plaza East, Suite 200
251 St. Asaphs Road
Bala Cynwyd, PA 19004
Cobe Laboratories, Inc. ............................................. 2,389,199 7.1%
1185 Oak Street
Lakewood, CO 80215
R. Douglas Armstrong, Ph.D.(5)....................................... 690,173 2.0%
Todd E. Simpson(6)................................................... 198,000 *
Brian S. Hampson(7).................................................. 42,300 *
Bruce W. Husel(8).................................................... 18,195 *
Mary L. Campbell(9).................................................. 16,825 *
Joseph A. Taylor(10)................................................. 10,383 *
Arthur F. Staubitz(11)............................................... 20,417 *
Fabrizio Bonanni(12)................................................. 833 *
Alan M. Wright(13)................................................... 983 *
All officers and directors as a group (9 persons)(14)................ 998,109 2.9%
</TABLE>
--------
* Represents less than 1% of the outstanding shares of Aastrom's common
stock.

(1) Except as indicated in the footnotes to this table, the persons named in
the table have sole voting and investment power with respect to all shares
of common stock shown as beneficially owned by them, subject to community
property laws, where applicable.

(2) Unless otherwise provided, the address for each beneficial owner is 24
Frank Lloyd Wright Drive, Ann Arbor, MI 48105.

(3) Calculated on the basis of 33,648,388 shares of common stock outstanding as
of August 31, 2000, except that shares of common stock underlying options
exercisable within 60 days of August 31, 2000 are deemed to be outstanding
for purposes of calculating ownership of securities of the holders of such
options.

(4) Includes 1,038,426 shares issuable upon exercise of warrants held by RGC
International Investors, LDC purchased on February 29, 2000 that are
exercisable until February 28, 2003.

(5) Includes 317,000 shares issuable upon exercise of options held by Dr.
Armstrong that are exercisable within the 60-day period following August
31, 2000. Also includes 28,000 shares held in trusts in which Dr. Armstrong
is a co-trustee; Dr. Armstrong disclaims beneficial ownership of all such
shares except to the extent of his pecuniary interest therein.

(6) Includes 193,000 shares issuable upon exercise of options held by Mr.
Simpson that are exercisable within the 60-day period following August 31,
2000.

(7) Includes 32,333 shares issuable upon exercise of options held by Mr.
Hampson that are exercisable within the 60-day period following August 31,
2000.

(8) Includes 16,695 shares issuable upon exercise of options held by Mr. Husel
that are exercisable within the 60-day period following August 31, 2000.

(9) Includes 14,583 shares issuable upon exercise of options held by Ms.
Campbell that are exercisable within the 60-day period following August 31,
2000. Also includes 1,842 shares of common stock held collectively by
Enterprise Management, Inc. and Enterprise Ventures, Limited Partnership,
which Ms. Campbell is an executive officer or partner of. Ms. Campbell
disclaims beneficial ownership of all such shares except to the extent of
her pecuniary interest therein.

2
<PAGE>

(10) Includes 9,583 shares issuable upon exercise of options held by Mr. Taylor
that are exercisable within the 60-day period following August 31, 2000.

(11) Includes 10,417 shares issuable upon exercise of options held by Mr.
Staubitz that are exercisable within the 60-day period following August
31, 2000.

(12) Consist of shares issuable upon exercise of options held by Dr. Bonanni
that are exercisable within the 60-day period following August 31, 2000.

(13) Includes 833 shares issuable upon exercise of options held by Mr. Wright
that are exercisable within the 60-day period following August 31, 2000

(14) Includes 595,278 shares issuable upon exercise of options that are
exercisable within the 60-day period following August 31, 2000.

3
<PAGE>

ELECTION OF DIRECTORS

Aastrom has a classified Board of Directors currently consisting of two
Class III directors (R. Douglas Armstrong and Joseph A. Taylor), two Class I
directors (Alan M. Wright and Fabrizio Bonanni) and two Class II directors
(Mary L. Campbell and Arthur F. Staubitz), who will serve until the Annual
Meetings of Shareholders to be held in 2000, 2001 and 2002, respectively, and
until their respective successors are duly elected and qualified. Directors in
a class are elected for a term of three years to succeed the directors in such
class whose terms expire at such annual meeting.

The nominees for election at the Annual Meeting of Shareholders to fill the
Class III positions on the Board of Directors are R. Douglas Armstrong, Ph.D.
and Joseph A. Taylor. If elected, the nominees will serve as directors until
Aastrom's Annual Meeting of Shareholders in 2003, and until their successors
are elected and qualified. If a nominee declines to serve or becomes
unavailable for any reason, or if a vacancy occurs before the election, the
proxies may be voted for such substitute nominee as the proxy holders may
designate.

If a quorum is present, the two nominees for the positions as Class III
directors receiving the highest number of votes will be elected. Abstentions
and broker non-votes will have no effect on the vote, except that abstentions
will be counted as shares present for purposes of determining the presence of a
quorum.

The table below sets forth for Aastrom's directors, including the Class III
nominees to be elected at this meeting, certain information, as of August 31,
2000, with respect to age and background.

<TABLE>
<CAPTION>
Director
Name Position With Aastrom Age Since
---- --------------------- --- --------

<S> <C> <C> <C>
Class III directors to be elected at the 2000 Annual Meeting of Shareholders:

R. Douglas Armstrong............. President and Chief Executive 47 1991
Officer, Chairman of the Board

Joseph A. Taylor................. Director 56 1998

Class I directors whose terms expire at the 2001 Annual Meeting of
Shareholders:

Alan M. Wright................... Director 55 2000

Fabrizio Bonanni................. Director 54 2000

Class II directors whose terms expire at the 2002 Annual Meeting of
Shareholders:

Mary L. Campbell................. Director 55 1998

Arthur F. Staubitz............... Director 61 1999
</TABLE>

Nominees for election at the 2000 Annual Meeting of Shareholders

R. Douglas Armstrong, Ph.D. joined Aastrom in June 1991, as a director and
as its President and Chief Executive Officer. From 1987 to 1991, Dr. Armstrong
served in different capacities, including as Executive Vice President and a
Trustee of the La Jolla Cancer Research Foundation (LJCRF), now named the
Burnham Institute, a 250-employee scientific research institute located in San
Diego, California. Dr. Armstrong received his doctorate in Pharmacology and
Toxicology from the Medical College of Virginia, and has held faculty and staff
positions at Yale University, University of California, San Francisco, LJCRF
and University of Michigan. Dr. Armstrong also serves on the Board of Directors
of Cytomedix, Inc.

Joseph A. Taylor a director since November 1998, currently serves as
Managing Director, Private Equity Finance at W. R. Hambrecht + Co., LLC, an
online merchant bank. Prior to joining W. R. Hambrecht + Co., Mr. Taylor was
the Director, Private Equity Investments at Munder Capital Management, an
investment

4
<PAGE>

management firm with $50 billion in assets under management. Mr. Taylor spent
15 years as a Senior Investment Analyst for the State Treasurer, State of
Michigan Retirement System, where he managed over $1.2 billion in private
equity investments. Mr. Taylor currently serves as a member of the Regional
Advisory Committee of Blue Care Network and previously served as a Director of
Spectrum Castings, Inc., and as Chairman of the Finance Committee of the Board
of Directors of Blue Care Network-East. Mr. Taylor holds a B. S. degree in
Finance from Chicago State University and an MBA from Illinois Governors State
University.

Directors Continuing In Office

Mary L. Campbell a director since January 1998, currently serves as
Principal and Vice President of EDM, Inc., the General Partner of the
Enterprise Development Fund II, L.P., a venture capital fund managing
approximately $26 million. Ms. Campbell is also a director of Centromine, Inc.
and Think & Do Software, Inc. Ms. Campbell received her Masters of Business
Administration (with Distinction) from the University of Michigan; her Master
of Special Education (with Honors) from Fairfield University; and her Bachelor
of Arts in English from the University of Michigan.

Arthur F. Staubitz a director since March 1999, most recently served as
Senior Vice President, Portfolio Strategy at Baxter International. He has also
served as Senior Vice President and General Counsel at both Baxter and Amgen,
Inc. During his career at Baxter, Mr. Staubitz served in a broad range of other
executive positions including Vice President, Business Development, Strategic
Planning and Law, Baxter Diagnostics; and Vice President and General Manager,
Ventures Group, Baxter World Trade Corporation. While at Baxter, Mr. Staubitz
managed corporate, litigation and regulatory legal groups; established
processes to identify, assess and fund strategic technology initiatives;
negotiated technology acquisitions and corporate partnerships; and helped to
establish the Baxter Diagnostic subsidiary. Prior to that Mr. Staubitz held
several positions at Sperry Univac and served as an Associate at the law firm
of Sidley & Austin. Mr. Staubitz received his A.B. (with Distinction and
Honors) from Wesleyan University and his Juris Doctorate (cum laude) from the
University of Pennsylvania Law School. Mr. Staubitz also serves on the Board of
Directors of Cytomedix, Inc.

Alan M. Wright a director since September 2000, currently serves as Senior
Vice President and Chief Financial Officer of CMS Energy and its principal
subsidiary, Consumers Energy. At CMS Energy, Mr. Wright has been responsible
for raising over $9 billion in capital through more than 50 transactions. Prior
to joining CMS Energy, Mr. Wright held various financial management positions
at Entergy Corporation, including Vice President of Finance where he raised $5
billion in capital through over 40 transactions. Mr. Wright earned his
Bachelor's degree in Economics from Cornell University. He has also completed
Stanford University's Executive Program, the Edison Electric Institute's (EEI)
Executive Leadership Program and post-graduate studies in Accounting at the
University of West Florida. Mr. Wright serves on the Finance Committee and the
Finance and Regulation Executive Advisory Committee of EEI, the Conference
Board council of Chief Financial Officers and on Jenkins' Special Committee to
the Financial Accounting Standards Board. Mr. Wright serves on the Board of
Directors of Ensure Technologies, a privately held company.

Fabrizio Bonanni a director since September 2000, currently serves as Senior
Vice President at Amgen Corporation, Inc. where he oversees Quality Control,
Quality Assurance, Regulatory Compliance and Environmental Health and Safety.
Previously, Dr. Bonanni held various management positions at Baxter
International from 1974 through 1999, most recently as Vice President,
Regulatory and Clinical Affairs and Corporate Vice President. Dr. Bonanni
earned his doctorate in Chemistry (magna cum laude and with mention of honor)
from the University of Florence, Italy and has done postdoctoral work in
physiological chemistry at the Massachusetts Institute of Technology. He is a
state-certified chemist and a member of the Ordine dei Chimici of Tuscany,
Italy. Dr. Bonanni is an alumnus of the Institute for International Management
at Northwestern University, J.L. Kellogg Graduate School of Management, and of
the Executive Program in Manufacturing at Harvard University, Graduate School
of Business Administration. Dr. Bonanni serves on the Board of Directors of the
California Healthcare Institute and Cytomedix Inc.

5
<PAGE>

During the fiscal year ended June 30, 2000, the Board of Directors held
twelve meetings. Each director serving on the Board of Directors in fiscal year
2000 attended at least 75% of such meetings of the Board of Directors and the
Committees on which he or she served.

Aastrom does not have a standing Nominating Committee, but does have an
Audit Committee and a Finance Committee. The Compensation Committee is
comprised of the entire Board.

The Audit Committee's function is to review with Aastrom's independent
accountants and management the annual financial statements and independent
accountants' opinion, review the scope and results of the examination of
Aastrom's financial statements by the independent accountants, review all
professional services performed and related fees by the independent
accountants, recommend the retention of the independent accountants to the
Board of Directors and periodically review Aastrom's accounting policies and
internal accounting and financial controls. The Audit Committee consists of
independent directors and were Mary L. Campbell and Joseph A. Taylor for fiscal
2000. During the fiscal year ended June 30, 2000, the Audit Committee held one
meeting.

The Compensation Committee's function is to review and approve salary and
bonus levels and stock option grants. Currently, the Compensation Committee is
composed of all members of Aastrom's Board of Directors. During the fiscal year
ended June 30, 2000, there were no separate meetings of the Compensation
Committee. For additional information concerning the Compensation Committee,
see "REPORT OF THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS ON
EXECUTIVE COMPENSATION" and "EXECUTIVE COMPENSATION AND OTHER MATTERS."

EXECUTIVE COMPENSATION AND OTHER MATTERS

The following table sets forth information for the fiscal years ended June
30, 1998, 1999 and 2000 concerning the compensation of the Chief Executive
Officer of Aastrom and each of Aastrom's other executive officers (Named
Executive Officers) as of June 30, 2000, whose total salary and bonus for the
year ended June 30, 2000, exceeded $100,000 for services rendered in all
capacities to Aastrom.

6
<PAGE>

SUMMARY COMPENSATION TABLE

<TABLE>
<CAPTION>
Long Term
Annual Compensation
Compensation Awards
-------------------- ------------------
Securities All Other
Name and Principal Position Year Salary Bonus Underlying Options Compensation
--------------------------- ---- -------- -------- ------------------ ------------
<S> <C> <C> <C> <C> <C>
R. Douglas Armstrong,
Ph.D. .................. 2000 $233,333 $262,500 317,000 --
President and Chief 1999 $244,167 -- 317,000 $22,031(1)
Executive Officer, 1998 $225,000 -- -- $ 9,735(1)
Chairman of the Board of
Directors

Todd E. Simpson.......... 2000 $152,500 $ 8,250 193,000 $10,962(1)
Vice President, Finance 1999 $150,000 -- 50,000 --
& Administration, Chief 1998 $136,667 -- 28,000 --
Financial Officer,
Secretary and Treasurer

Brian S. Hampson(3)...... 2000 $103,258 $ 56,250 54,000 --
Vice President, Product
Development

Bruce W. Husel .......... 2000 $127,500 $ 26,532 85,000 --
Vice President, Quality 1999 $125,000 -- 50,000 --
Systems and Regulatory 1998 $ 74,792(4) -- 35,000 $51,928(2)
Affairs
</TABLE>
--------
(1) Consists of vacation pay.

(2) Consists of relocation or temporary living expenses.

(3) Mr. Hampson was promoted to Vice President in June 2000.

(4) Mr. Husel joined Aastrom in November 1997.

The following table provides information with respect to stock option grants
to the Named Executive Officers during the year ended June 30, 2000.

Option Grants In Last Fiscal Year

<TABLE>
<CAPTION>
Potential
Individual Grants Realizable Value at
---------------------------------------------- Assumed Annual
Number of % of Total Rates of Stock
Securities Options Price Appreciation
Underlying Granted to Exercise or for Option Term(1)
Options Employees in Price Per Expiration -------------------
Name Granted(2) 2000 Share(2) Date 5% 10%
---- ---------- ------------ ----------- ---------- --------- ---------
<S> <C> <C> <C> <C> <C> <C>
R. Douglas Armstrong,
Ph.D. ................. 317,000 30.0% $ .84375 12/15/09 $ 435,678 $ 693,745

Todd E. Simpson......... 193,000 18.2% $ .84375 12/15/09 $ 265,255 $ 422,375

Brian S. Hampson........ 14,000 1.3% $ .84375 12/15/09 $ 19,241 $ 30,639
40,000 3.8% $2.62500 6/21/10 171,034 272,343

Bruce W. Husel.......... 85,000 8.0% $ .84375 12/15/09 $ 116,822 $ 186,020
</TABLE>
--------
(1) Potential gains are net of exercise price, but before taxes associated with
exercise. These amounts represent certain assumed rates of appreciation
only, in accordance with the Securities and Exchange Commission's rules.
Actual gains, if any, on stock option exercises are dependent on the future
performance of the common stock, overall market conditions and the
optionholders continued employment through the vesting period. The amounts
reflected in this table may not necessarily be achieved.

(2) Each of these options was granted under Aastrom's Amended and Restated 1992
Incentive and Non-Qualified Stock Option Plan (Option Plan) at an exercise
price equal to the fair market value of the common stock on the date of
grant. Stock options held by Dr. Armstrong, Mr. Simpson and Mr. Hampson are
fully vested pursuant to executive Pay to Stay Severance Agreement executed
with such executives in October 1999. Mr. Husel's stock option vests
ratably through December 2002, subject to continued employment with
Aastrom. See "--Severance and Change of Control Arrangements."

7
<PAGE>

The following table provides information with respect to exercises of stock
options during the year ended June 30, 2000, and unexercised options held as of
June 30, 2000, by the Named Executive Officers.

Aggregated Option Exercises
And Fiscal Year-End Option Values

<TABLE>
<CAPTION>
Number of Shares Value of Unexercised
Underlying Unexercised In-the-Money Options
Shares Options at June 30, 2000 at June 30, 2000(2)
Acquired Value ------------------------- -------------------------
Name on Exercise Realized(1) Exercisable Unexercisable Exercisable Unexercisable
---- ----------- ----------- ----------- ------------- ----------- -------------
<S> <C> <C> <C> <C> <C> <C>
R. Douglas Armstrong,
Ph.D................... -- -- 317,000 -- $495,313 --
Todd E. Simpson......... -- -- 193,000 -- $301,563 --
Brian S. Hampson........ 9,000 $ 32,488 32,333 40,000 $ 28,377 --
Bruce W. Husel.......... 29,000 $183,969 11,380 44,620 $ 17,781 $69,719
</TABLE>
--------
(1) "Value Realized" represents the fair market value of the underlying shares
of common stock on the exercise date, minus the aggregate exercise price of
such options.

(2) The value of "in-the-money" stock options represents the difference between
the exercise price of such options and the fair market value of $2.41 per
share of common stock as of June 30, 2000, the closing price of the common
stock reported on the Nasdaq National Market on such date.

Severance and Change of Control Arrangements

Aastrom entered into employment agreements with no defined length of
employment with Todd E. Simpson, Bruce W. Husel and Brian S. Hampson in
December 1995, November 1997 and July 1993, respectively. Pursuant to these
agreements, Aastrom agreed to pay Messrs. Simpson, Husel and Hampson annual
base salaries of $122,500, $110,000 and $70,000, respectively, which base
salaries have been increased and are subject to periodic review and adjustment.
Pursuant to the terms of the foregoing employment agreements, either party may
generally terminate the employment relationship without cause at any time upon
14 days prior written notice to the other party or immediately with cause upon
notice. Aastrom has also entered into an Indemnification Agreement with certain
of its directors, officers and other key personnel.

In the event of a transfer of control of Aastrom, as defined under the
Option Plan, Aastrom must cause any successor corporation to assume the options
or substitute similar options for outstanding options or continue such options
in effect. In the event that any successor to Aastrom in a merger,
consolidation or dissolution will not assume the options or substitute similar
options, then the options become exercisable in full and such options will be
terminated if not exercised prior to such merger, consolidation or dissolution.
The vesting of certain options granted to executive officers of Aastrom
accelerates if such officer is terminated following a transfer of control.

Options granted under Aastrom's 1996 Outside Directors Stock Option Plan
(Directors Plan) contain provisions pursuant to which all outstanding options
granted under the Directors Plan will become fully vested and immediately
exercisable upon a "transfer of control," as defined under the Directors Plan.

Aastrom is a party to an Executive Retention and Severance Agreement with
Dr. Armstrong. Under the terms of this agreement, in the event of Dr.
Armstrong's termination upon a change of control, he will be entitled to
receive a lump sum severance payment of the maximum amount which, when added to
other compensation and benefits treated as parachute payments under the
Internal Revenue Code, does not result in any compensation or benefit becoming
subject to an excise tax pursuant to Section 4999 of the Internal Revenue Code.
Upon any termination of Dr. Armstrong's employment (other than for cause),
Aastrom will be required to reimburse him for his costs (incurred within one
year of termination of employment) for relocating to any other location in the
United States, up to a maximum of $50,000. Aastrom has also agreed to provided
Dr. Armstrong with a severance payment equal to 18 months of his then current
salary should he be terminated (other than for cause) upon a change in control
of Aastrom.

8
<PAGE>

Aastrom is a party to Retention Bonus Agreements with each of Messrs.
Simpson, Husel and Hampson, that provide for a lump sum severance payment equal
to six times each employee's then current monthly salary and relocation expense
reimbursement of up to a maximum of $25,000 in the event of employee's loss of
employment upon certain change in control events. These agreements also provide
for retention bonus payments equal to six times each employee's then current
monthly salary upon the one-year anniversary of an Acquisition or Merger
Transaction, as defined, provided that the employee remains employed during
such one-year period. The employee is entitled to the retention bonus in the
event of their termination (other than for cause), during such one-year period.
Messrs. Simpson, Husel and Hampson are also parties to Relocation Bonus
Agreements with Aastrom. Upon a Merger Transaction, as defined, that requires
more than a 50-mile relocation of the employee's place of employment, a lump
sum payment equal to six times each employee's then current monthly salary may
be paid upon the one year anniversary of the employee's relocation, provided
that they remain employed by Aastrom.

Aastrom is party to Pay to Stay Severance Agreements that were executed in
October 1999 with certain employees including, Dr. Armstrong, Mr. Simpson and
Mr. Hampson. Pursuant to these agreements, an Incentive Sale Bonus, as defined,
may become payable in the event that Aastrom sells its assets or participates
in a merger or acquisition transaction. Any employee who voluntarily terminates
their employment with Aastrom prior to substantial completion of such a
transaction will forego their participation in the Incentive Bonus Pool, with
their share of the pool being allocated to the remaining participants.

Changes to Benefit Plans

1996 Outside Directors Stock Option Plan. Aastrom has proposed the approval
of an amendment to its 1996 Outside Directors Stock Option Plan (the Directors
Plan) to (i) increase the maximum aggregate number of shares of Aastrom's
common stock issuable under the Directors Plan by 150,000 shares from 150,000
shares to 300,000 shares; and (ii) to increase the size of Initial Option Grant
and Annual Options granted after the date of the 2000 Annual Meeting of
Shareholders from 5,000 shares to 10,000 shares as described below under the
caption, "APPROVAL OF AMENDMENTS TO 1996 OUTSIDE DIRECTORS STOCK OPTION PLAN."
If the proposed amendments to the Directors Plan are approved, each of Mr.
Taylor, Ms. Campbell and Mr. Staubitz will receive on the day following the
2000 Annual Meeting of Shareholders an Annual Option to purchase 10,000 shares.
Mr. Wright and Dr. Bonnani each received Initial Options to purchase 5,000
shares of common stock upon becoming directors in September 2000.

1992 Incentive and Non-Qualified Stock Option Plan. Aastrom also has
proposed the approval of an amendment to its 1992 Incentive and Non-Qualified
Stock Option Plan (the Option Plan) to increase the maximum aggregate number of
shares of Aastrom's common stock issuable under the Option Plan by
1,400,000 shares from 3,300,000 shares to 4,700,000 shares, as described below
under the caption, "APPROVAL OF AMENDMENT TO 1992 INCENTIVE AND NON-QUALIFIED
STOCK OPTION PLAN." Grants of stock under the Option Plan are made at the
discretion of Board of Directors. Accordingly, future grants under the Option
Plan are not determinable. Non-employee directors are not eligible to
participate in the Option Plan.

Compensation of Directors

Each non-employee director of Aastrom receives a cash payment of $1,000 for
each meeting of the Board of Directors attended in person, a $1,000 cash
payment for participation in a committee meeting of the Board of Directors on
which they serve, and a cash payment of $500 for each telephonic meeting of the
Board of Directors attended telephonically. In addition, directors receive
reimbursement for expenses incurred in attending each Board of Directors and
committee meeting. Aastrom's Directors Plan currently provides for the initial
automatic grant of an option to purchase 5,000 shares of Aastrom's common stock
to each outside director of Aastrom upon initial appointment or election to the
Board of Directors, and subsequent grants to each outside director of an option
to purchase 5,000 shares of common stock on the date of each Annual Meeting of
Shareholders, provided the outside director continues to serve in that capacity
and has so served for at least six months.

9
<PAGE>

Compensation Committee Interlocks and Insider Participation

Each member of the Board of Directors served as a member of the Compensation
Committee during fiscal year ended June 30, 2000. During that fiscal year, R.
Douglas Armstrong was employed by Aastrom as its President and Chief Executive
Officer and also served as Chairman of the Board of Directors.

Certain Transactions

In November 1998, Aastrom and Cobe Laboratories, Inc. entered into a
Termination and Transition Agreement, pursuant to which the parties agreed to
terminate the Distribution Agreement entered into in October 1993. Among other
things, Cobe made a cash payment to Aastrom of $1,237,000 in connection with
the Termination and Transition Agreement.

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Securities Exchange Act of 1934, as amended, requires
Aastrom's executive officers, directors and persons who beneficially own more
than 10% of Aastrom's common stock to file initial reports of ownership and
reports of changes in ownership with the Securities and Exchange Commission
(SEC). Such persons are required by SEC regulations to furnish Aastrom with
copies of all Section 16(a) forms filed by such persons.

Based solely on Aastrom's review of such forms furnished to it and written
representations from certain reporting persons, Aastrom believes that all
filing requirements applicable to its executive officers, directors and more
than 10% shareholders were complied with.

REPORT OF THE COMPENSATION COMMITTEE
OF THE BOARD OF DIRECTORS ON EXECUTIVE COMPENSATION

The Compensation Committee is composed of all members of Aastrom's Board of
Directors and, as such, the Compensation Committee does not hold separate
meetings.

In fiscal year 2000, the Compensation Committee was responsible for setting
and administering the policies governing annual compensation of the executive
officers of Aastrom. These policies are based upon the philosophy that
Aastrom's long-term success is best achieved through recruitment and retention
of the best people possible. The Compensation Committee applied this philosophy
in determining compensation for Aastrom's executive officers in three areas:
salary, bonuses and stock options.

Salary. Aastrom strives to offer salaries to its executive officers which
are competitive in its industry and in its geographic region for similar
positions requiring similar qualifications. In determining executive officers'
salaries, the Compensation Committee considers salary surveys of companies in
similar industries, and of similar size and geographic location. Companies
selected for salary comparisons are not necessarily the same companies used to
compare stock performance in the chart under the heading "Comparison Of
Shareholder Return."

The Compensation Committee generally evaluates the performance and sets the
salary of Aastrom's Chief Executive Officer, Dr. Armstrong, on an annual basis.
Dr. Armstrong evaluates the performance of all other executive officers, and
recommends salary adjustments which are subject to review and approval by the
Compensation Committee. Performance evaluations for individual executive
officers are based on individual goals. For Dr. Armstrong, these goals are set
by the Compensation Committee and, for all other officers, these goals are set
by Dr. Armstrong. The goals of executive officers are based on their individual
management responsibilities. In addition to reviewing the results of the
performance evaluations and information concerning competitive salaries, the
Compensation Committee and Dr. Armstrong consider the financial condition of
Aastrom in evaluating salary adjustments. The salaries are evaluated by the
Compensation Committee, with each member using his personal judgment and
subjective factors to assess performance.

10
<PAGE>

Bonuses. Aastrom seeks to provide additional incentives and rewards to
executives who make contributions of outstanding value to Aastrom. For this
reason, Aastrom may award incentive compensation which can comprise a
substantial portion of the total compensation of executive officers when earned
and paid. Cash bonuses are based on a subjective evaluation of performance and
existing salary, rather than a specific formula.

Stock Options. The Compensation Committee believes that employee equity
ownership provides significant additional incentive to executive officers to
maximize value for Aastrom's shareholders, and therefore makes periodic grants
of stock options under Aastrom's Option Plan. Such options are granted at the
prevailing market price, and will only have value if Aastrom's stock price
increases over the exercise price. Therefore, the Compensation Committee
believes that stock options serve to align the interest of executive officers
closely with other shareholders because of the direct benefit executive
officers receive through improved stock performance.

In fiscal year 2000, the Compensation Committee made determinations
concerning the size and frequency of option grants for executive officers,
after consideration of recommendations from the Chief Executive Officer. Option
grants were based upon relative position and responsibilities of each executive
officer, historical and expected contributions of each officer to Aastrom, and
previous option grants to such executive officers. Options were granted with a
goal to provide competitive equity compensation for executive officers compared
to executive officers of similar rank in companies of Aastrom's industry,
geographic location and size. Generally, option grants vest over four years,
although the board may at its discretion grant options with shorter vesting
schedules or that vest immediately. Option grants for fiscal year 2000 are set
forth in the table entitled "Option Grants in Last Fiscal Year" in the section
entitled "Executive Compensation and Other Matters."

COMPENSATION COMMITTEE

R. Douglas Armstrong
Mary L. Campbell
Joseph A. Taylor
Arthur F. Staubitz

11
<PAGE>

COMPARISON OF SHAREHOLDER RETURN

Set forth below is a line graph comparing changes in the cumulative total
return on Aastrom's common stock, a broad market index (the Nasdaq Stock
Market-U.S. Index (Nasdaq Index)) and an industry index (those companies that
selected the same first three digits of their primary Standard Industrial
Classification Code Number as Aastrom, 283, and have a market capitalization of
less than $200 million (Industry Index)) for the period commencing on February
4, 1997, the date the common stock commenced trading on the Nasdaq National
Market, and ending on June 30, 2000.

Comparison of Cumulative Total Return
From February 4, 1997 through June 30, 2000

Aastrom Biosciences, Inc. Industry Index and Nasdaq Index

[PERFORMANCE GRAPH APPEARS HERE]

<TABLE>
<CAPTION>
2/4/97 6/30/97 12/31/97 6/30/98 12/31/98 6/30/99 12/31/99 6/30/00
Aastrom/Index........... ------- ------- -------- ------- -------- ------- -------- -------
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Aastrom................. $100.00 $101.8 $ 62.5 $ 53.6 $ 41.1 $ 17.9 $ 11.2 $ 34.4
Nasdaq Index............ 100.00 105.0 115.0 138.2 162.0 198.8 301.1 293.7
Industry Index.......... 100.00 86.1 82.3 72.6 55.7 43.4 43.9 77.1
</TABLE>
--------
(1) Assumes that $100.00 was invested on February 4, 1997 in Aastrom's common
stock and each index, and that all dividends were reinvested. No cash
dividends have been declared on Aastrom's common stock. Shareholder returns
over the indicated period should not be considered indicative of future
shareholder returns.

12
<PAGE>

PROPOSAL 1

ELECTION OF DIRECTORS

If a quorum is present, either in person or by proxy, the two nominees for
the positions as Class III directors receiving the highest number of votes will
be elected. Abstentions and broker non-votes will have no effect on the vote,
except that abstentions will be counted as shares present for purposes of
determining the presence of a quorum. The Board of Directors Unanimously
Recommends a Vote "FOR" the Nominees Named Above.

PROPOSAL 2

APPROVAL OF AMENDMENT TO THE 1992 INCENTIVE AND
NON-QUALIFIED STOCK OPTION PLAN TO INCREASE
THE NUMBER OF SHARES ISSUABLE UNDER THE PLAN BY 1,400,000

Aastrom's 1992 Incentive and Non-Qualified Stock Option Plan (Option Plan)
was adopted by the Board of Directors on April 24, 1992. As of September 1,
2000, 1,458,544 shares remained available for future option grants under the
Option Plan. Given the expected addition of employees, particularly executive-
level employees, the Board of Directors believes this amount is insufficient to
satisfy Aastrom's anticipated equity incentive objectives. Accordingly, the
Board of Directors has approved, subject to shareholder approval, the
reservation of an additional 1,400,000 shares of common stock for issuance
under the Option Plan.

The shareholders are now being asked to approve the increase from 3,300,000
shares to 4,700,000 shares as the maximum aggregate number of shares that may
be issued under the Option Plan. The Board of Directors believes that approval
of this amendment is in the best interests of Aastrom and its shareholders
because the availability of an adequate stock option program is an important
factor in attracting, motivating and retaining qualified officers, employees
and consultants essential to the success of Aastrom and in aligning their long-
term interests with those of the shareholders.

Vote Required and Board of Director's Recommendation.

The affirmative vote of a majority of the votes cast at the Annual Meeting
of Shareholders at which a quorum is present and voting, either in person or by
proxy, is required for approval of this proposal. Abstentions will have the
same effect as a negative vote. Broker non-votes will have no effect on the
outcome of the vote.

The Board of Directors believes that approval of the increase in the number
of shares issuable under the Option Plan is in the best interests of Aastrom
and the shareholders for the reasons stated above. Therefore, the Board of
Directors Unanimously Recommends a Vote "FOR" Approval of This Proposal.

13
<PAGE>

Summary of the Provisions of the Option Plan.

The following summary of the Option Plan, as amended, is qualified in its
entirety by the specific language of the Option Plan, a copy of which is
available to any shareholder upon request.

General. The Option Plan provides for the grant of incentive stock options
within the meaning of section 422 of the Code and nonstatutory stock options.
As of September 1, 2000, Aastrom had options to purchase an aggregate of
1,140,014 shares at a weighted average exercise price of $1.39 per share
outstanding under the Option Plan. The exercise price of all options granted
under the Option Plan has been at least equal to the fair market value per
share of the common stock on the date of grant as determined in good faith by
the Board of Directors. As of September 1, 2000, options to purchase 701,442
shares of common stock granted pursuant to the Option Plan had been exercised,
and 2,858,544 shares of common stock remained available for future grants under
the Option Plan, provided that the shareholders approve the increase in the
number of shares authorized under the Option Plan and approved by the Board of
Directors.

Shares Subject to Plan. The Board has amended the Option Plan, subject to
shareholder approval, to increase by 1,400,000 the maximum number of authorized
but unissued or reacquired shares of Aastrom's common stock issuable thereunder
to an aggregate of 4,700,000. In the event of any stock dividend, stock split,
reverse stock split, recapitalization, combination, reclassification, or
similar change in the capital structure of Aastrom, appropriate adjustments
will be made to the shares subject to the Option Plan, to the grant limit, as
defined, and to outstanding options. To the extent any outstanding option under
the Option Plan expires or terminates prior to exercise in full or if shares
issued upon exercise of an option are repurchased by Aastrom, the shares of
common stock for which such option is not exercised or the repurchased shares
are returned to the Option Plan and become available for future grant.

Administration. The Option Plan is administered by the Board of Directors or
a duly appointed committee of the Board. With respect to the participation of
individuals whose transactions in Aastrom's equity securities are subject to
Section 16 of the Securities Exchange Act of 1934 (Exchange Act), the Option
Plan must be administered in compliance with the requirements, if any, of Rule
16b-3 under the Exchange Act. Subject to the provisions of the Option Plan, the
Board determines the persons to whom options are to be granted, the number of
shares to be covered by each option, whether an option is to be an incentive
stock option or a nonstatutory stock option, the terms of exercisability of
each option and the vesting of the shares acquired, including the effect
thereon of an optionee's termination of service, the exercise price and type of
consideration to be paid to Aastrom upon exercise of an option, the duration of
each option, and all other terms and conditions of the options. The Option Plan
authorizes the Board to amend, modify, extend or renew, or grant a new option
in substitution for, any option, to waive any restrictions or conditions
applicable to any option or any shares acquired upon the exercise thereof.
Subject to certain limitations, the Option Plan provides for indemnification by
Aastrom of any director, officer or employee against all reasonable expenses,
including attorneys' fees, incurred in connection with any legal action arising
from such person's action or failure to act in administering the Option Plan.
The Board will interpret the Option Plan and options granted thereunder, and
all determinations of the Board will be final and binding on all persons having
an interest in the Option Plan or any option.

Eligibility. All employees, directors and consultants of Aastrom or of any
present or future parent or subsidiary corporations of Aastrom are eligible to
participate in the Option Plan. In addition, options may be granted to
prospective employees, consultants and directors in connection with written
offers of employment or engagement. However, any such options may not become
exercisable prior to such individual's commencement of service. As of September
1, 2000, Aastrom had approximately 30 full time equivalent employees, including
four executive officers, and had four directors, one of which was an employee.
Any person eligible under the Option Plan may be granted a nonstatutory option.
However, only employees may be granted incentive stock options. Two advisors to
Aastrom hold options under the Option Plan as of September 1, 2000.

Terms and Conditions of Options. Each option granted under the Option Plan
is evidenced by a written agreement between Aastrom and the optionee specifying
the number of shares subject to the option and the

14
<PAGE>

other terms and conditions of the option, consistent with the requirements of
the Option Plan. The exercise price per share must equal at least the fair
market value of a share of Aastrom's common stock on the date of grant of an
incentive stock option and at least 85% of the fair market value of a share of
the common stock on the date of grant of a nonstatutory stock option. The
exercise price of any option granted to a person who at the time of grant owns
stock possessing more than 10% of the total combined voting power of all
classes of stock of Aastrom or any parent or subsidiary corporation of Aastrom
(Ten Percent Shareholder) must be at least 110% of the fair market value of a
share of Aastrom's common stock on the date of grant. On September 27, 2000,
the closing price of a share of Aastrom's common stock was $2.94, as reported
on the Nasdaq National Market.

Generally, the exercise price may be paid in cash, by check, or in cash
equivalent, by tender of shares of Aastrom's common stock owned by the optionee
having a fair market value not less than the exercise price, by the assignment
of the proceeds of a sale or loan with respect to some or all of the shares of
common stock being acquired upon the exercise of the option, by means of a
promissory note, by any other lawful consideration approved by the Board or by
any combination of these. The Board may restrict the forms of payment permitted
in connection with any option grant.

Options granted under the Option Plan will become exercisable and vested at
such times and subject to such conditions as specified by the Board. Generally,
options granted under the Option Plan are exercisable on and after the date of
grant, subject to the right of Aastrom to reacquire at the optionee's exercise
price any unvested shares held by the optionee upon termination of employment
or service with Aastrom or if the optionee attempts to transfer any unvested
shares (Unvested Share Repurchase Option). Shares subject to options generally
vest in installments subject to the optionee's continued employment or service.
The maximum term of an option granted under the Option Plan is ten years,
except that an incentive stock option granted to a Ten Percent Shareholder may
not have a term longer than five years.

Options are nontransferable by the optionee other than by will or by the
laws of descent and distribution, and are exercisable during the optionee's
lifetime only by the optionee.

Change in Control. In the event of a transfer of control of Aastrom, as
defined under the Option Plan, Aastrom must cause any successor corporation to
assume the options or substitute similar options for outstanding options or
continue such options in effect. In the event that any successor to Aastrom in
a merger, consolidation or dissolution will not assume the options or
substitute similar options, then the options become exercisable in full and
such options will be terminated if not exercised prior to such merger,
consolidation or dissolution. The vesting of certain options accelerates if
such officer is terminated following a transfer of control.

Termination or Amendment. The Option Plan will continue in effect until the
earlier of its termination by the Board or the date on which all shares
available for issuance under the Option Plan have been issued and all
restrictions on such shares under the terms of the Option Plan and the option
agreements have lapsed, provided that all options must be granted by April 24,
2002, which is ten years from the date the Board approved the Option Plan. The
Board may terminate or amend the Option Plan at any time. However, subject to
changes in the law that would permit otherwise, without shareholder approval,
the Board may not adopt an amendment to the Option Plan which would increase
the total number of shares of common stock issuable thereunder, change the
class of persons eligible to receive incentive stock options, or otherwise
require approval of Aastrom's shareholders under any applicable law, regulation
or rule. No amendment may adversely affect an outstanding option without the
consent of the optionee, unless the amendment is required to preserve the
option's status as an incentive stock option or is necessary to comply with any
applicable law.

Summary of Federal Income Tax Consequences of the Option Plan.

The following summary is intended only as a general guide as to the United
States federal income tax consequences under current law of participation in
the Option Plan and does not attempt to describe all possible federal or other
tax consequences of such participation or tax consequences based on particular
circumstances.

15
<PAGE>

Incentive Stock Options. An optionee recognizes no taxable income for
regular income tax purposes as the result of the grant or exercise of an
incentive stock option qualifying under section 422 of the Code. Optionees who
do not dispose of their shares for two years following the date the option was
granted nor within one year following the exercise of the option will normally
recognize a long-term capital gain or loss equal to the difference, if any,
between the sale price and the purchase price of the shares. If an optionee
satisfies such holding periods upon a sale of the shares, Aastrom will not be
entitled to any deduction for federal income tax purposes. If an optionee
disposes of shares within two years after the date of grant or within one year
from the date of exercise, the difference between the fair market value of the
shares on the determination date (see discussion under "Nonstatutory Stock
Options" below) and the option exercise price (not to exceed the gain realized
on the sale if the disposition is a transaction with respect to which a loss,
if sustained, would be recognized) will be taxed as ordinary income at the time
of disposition. Any gain in excess of that amount will be a capital gain. If a
loss is recognized, there will be no ordinary income, and such loss will be a
capital loss. A capital gain or loss will be mid-term if the optionee's holding
period is between 12 and 18 months or long-term if the optionee's holding
period is more than 18 months. Any ordinary income recognized by the optionee
upon the disqualifying disposition of the shares generally should be deductible
by Aastrom for federal income tax purposes, except to the extent such deduction
is limited by applicable provisions of the Code or the regulations thereunder.
The difference between the option exercise price and the fair market value of
the shares on the determination date of an incentive stock option (see
discussion under "Nonstatutory Stock Options" below) is an adjustment in
computing the optionee's alternative minimum taxable income and may be subject
to an alternative minimum tax which is paid if such tax exceeds the regular tax
for the year. Special rules may apply with respect to certain subsequent sales
of the shares in a disqualifying disposition, certain basis adjustments for
purposes of computing the alternative minimum taxable income on a subsequent
sale of the shares and certain tax credits which may arise with respect to
optionees subject to the alternative minimum tax.

Nonstatutory Stock Options. Options not designated or qualifying as
incentive stock options will be nonstatutory stock options. Nonstatutory stock
options have no special tax status. An optionee generally recognizes no taxable
income as the result of the grant of such an option. Upon exercise of a
nonstatutory stock option, the optionee normally recognizes ordinary income in
the amount of the difference between the option exercise price and the fair
market value of the shares on the determination date (as defined below). If the
optionee is an employee, such ordinary income generally is subject to
withholding of income and employment taxes. The "determination date" is the
date on which the option is exercised unless the shares are subject to a
substantial risk of forfeiture and are not transferable, in which case the
determination date is the earlier of (i) the date on which the shares are
transferable, or (ii) the date on which the shares are not subject to a
substantial risk of forfeiture. If the determination date is after the exercise
date, the optionee may elect, pursuant to section 83(b) of the Code, to have
the exercise date be the determination date by filing an election with the
Internal Revenue Service not later than 30 days after the date the option is
exercised. Upon the sale of stock acquired by the exercise of a nonstatutory
stock option, any gain or loss, based on the difference between the sale price
and the fair market value on the determination date, will be taxed as capital
gain or loss. A capital gain or loss will be mid-term if the optionee's holding
period is between 12 and 18 months or long-term if the optionee's holding
period is more than 18 months. No tax deduction is available to Aastrom with
respect to the grant of a nonstatutory option or the sale of the stock acquired
pursuant to such grant. Aastrom generally should be entitled to a deduction
equal to the amount of ordinary income recognized by the optionee as a result
of the exercise of a nonstatutory option, except to the extent such deduction
is limited by applicable provisions of the Code or the regulations thereunder.

In October 1998, the board reduced the exercise price of options held by
non-executive employees to the then current fair market value of Aastrom's
common stock. In December 1999, each executive officer received a new stock
option award to purchase an equal the number of shares covered by stock option
agreements held at that time. In return, each executive officer surrendered
their previously held stock option agreements. The exercise price of the newly
granted stock options were set to the then current fair market value of
Aastrom's common stock with the vesting schedule set to approximate the
remaining vesting schedule of the stock option agreements surrendered.

16
<PAGE>

PROPOSAL 3

APPROVAL OF AMENDMENTS TO 1996 OUTSIDE DIRECTORS STOCK OPTION PLAN

General

Aastrom's 1996 Outside Directors Stock Option Plan (the Directors Plan) was
adopted by the Board of Directors in 1996 with an initial reserve of 150,000
shares of common stock. Excluding the proposed increase in the share reserve
and the new grants of options to purchase shares of common stock under the
Directors Plan as described below and in "EXECUTIVE COMPENSATION AND OTHER
MATTERS--Changes to Benefit Plans: 1996 Outside Directors Stock Option Plan,"
as of September 1, 2000, 100,000 shares remained available for future option
grants under the Directors Plan. The Board has amended the Directors Plan,
subject to shareholder approval, to (i) increase by 150,000 shares from 150,000
shares to 300,000 shares the maximum aggregate number of shares of common stock
issuable under the Directors Plan; and (ii) to increase the size of Initial
Option Grant and Annual Options granted after the date of the 2000 Annual
Meeting of Shareholders from 5,000 shares to 10,000 shares.

The shareholders are now being asked to approve amendments to (i) increase
the maximum aggregate number of shares of common stock issuable under the
Directors Plan; and (ii) to increase the size of Annual Options granted after
the date of the 2000 Annual Meeting of Shareholders. The Board believes that
the availability of an adequate Directors Plan reserve is an important factor
in attracting, motivating and retaining qualified outside directors essential
to the success of Aastrom and in aligning their long-term interests with those
of the shareholders. Because competition for highly qualified individuals in
the industry is intense, management believes that to successfully attract the
best candidates, Aastrom must offer a competitive stock option program as an
essential component of its compensation packages. The Board of Directors
further believes that stock options serve an important role in motivating their
holders to contribute to Aastrom's continued growth and profitability. The
proposed amendments are intended to ensure that the Directors Plan will
continue to have, attract and retain well-qualified directors.

Vote Required and Board of Director's Recommendation

The affirmative vote of a majority of the shares present or represented by
proxy and entitled to vote at the Annual Meeting, at which a quorum
representing a majority of all outstanding shares of common stock of Aastrom is
present and voting, either in person or by proxy, is required for approval of
this proposal. Abstentions and broker non-votes each will be counted as present
for purposes of determining the presence of a quorum. Abstentions will have the
same effect as a negative vote on this proposal. Broker non-votes will have no
effect on the outcome of this vote.

The Board believes that the proposed amendments to the Directors Plan to (i)
increase to 300,000 the number of shares of Aastrom's common stock issuable
under the Directors Plan; and (ii) to increase the size of Annual Options
granted after the date of the 2000 Annual Meeting of Shareholders from 5,000
shares to 10,000 shares is in the best interest of Aastrom for the reasons
stated above. Therefore, the Board of Directors Unanimously Recommends a Vote
"FOR" Approval of This Proposal.

Description of Plan

The following summary of the Directors Plan is qualified in its entirety by
the specific language of the Directors Plan, a copy of which is available to
any shareholder upon request.

General. The Directors Plan provides for the automatic grant of nonstatutory
stock options to nonemployee directors of Aastrom and is intended to qualify as
a "formula plan" within the meaning of Rule 16b-3 under the Exchange Act.

Shares Subject to Plan. Currently, a maximum of 150,000 shares of the
authorized but unissued or reacquired shares of the common stock of Aastrom may
be issued upon the exercise of options granted under

17
<PAGE>

the Directors Plan. Upon any stock dividend, stock split, reverse stock split,
recapitalization, combination, reclassification, or similar change in the
capital structure of Aastrom, appropriate adjustments will be made to the
shares subject to the Directors Plan, to the terms of the automatic option
grants described below, and to outstanding options. To the extent that any
outstanding option under the Directors Plan expires or terminates prior to
exercise in full or if shares issued upon the exercise of an option are
repurchased by Aastrom, the shares of common stock for which such option is not
exercised or the repurchased shares are returned to the plan and become
available for future grants.

Administration. The Directors Plan is intended to operate automatically
without discretionary administration. To the extent administration is
necessary, it will be performed by the Board of Directors or a duly appointed
committee of the Board. However, the Board has no discretion to select the
nonemployee directors of Aastrom who are granted options under the Directors
Plan, to set the exercise price of such options, to determine the number of
shares for which or the time at which particular options are granted or to
establish the duration of such options. The Directors Plan provides, subject to
certain limitations, for indemnification by Aastrom of any director, officer or
employee against all reasonable expenses, including attorneys' fees, incurred
in connection with any legal action arising from such person's action or
failure to act in administering the Directors Plan. The Board is authorized to
interpret the Directors Plan and options granted thereunder, and all
determinations of the Board will be final and binding on all persons having an
interest in the Directors Plan or any option.

Eligibility. Only directors of Aastrom who are not at the time of option
grant employees of Aastrom or of any parent or subsidiary corporation of
Aastrom (the Outside Directors) are eligible to participate in the Directors
Plan. Currently, Aastrom has five Outside Directors.

Automatic Grant of Options. Currently, the Directors Plan provides that each
Outside Director first elected or appointed to the Board after the Effective
Date of the plan will be granted automatically, on the date of such initial
election or appointment, an option to purchase 5,000 shares of common stock. An
option granted on the Effective Date of the plan or on the date of initial
appointment or election as an Outside Director is referred to herein as an
Initial Option. The Directors Plan also currently provides for the automatic
annual grant, on the day following each annual meeting of the shareholders of
Aastrom, of an additional option to purchase 5,000 shares of common stock (an
Annual Option) to each Outside Director remaining as a member of the Board
(including a director who previously did not qualify as an Outside Director but
who subsequently qualifies) other than an Outside Director receiving an Initial
Option on the day following the annual meeting. It is proposed that the size of
the Initial Option grant and Annual Option granted after the date of the 2000
Annual Meeting of Shareholders be increased from 5,000 shares to 10,000 shares.

Terms and Conditions of Options. Each option granted under the Directors
Plan is evidenced by a written agreement between Aastrom and the Outside
Director specifying the number of shares subject to the option and the other
terms and conditions of the option, consistent with the requirements of the
Directors Plan. The exercise price of any option granted under the Directors
Plan must equal the fair market value, as determined pursuant to the plan, of a
share of Aastrom's common stock on the date of grant. Generally, the fair
market value of the common stock will be the closing price per share on the
date of grant as reported on the Nasdaq National Market. No option granted
under the Directors Plan is exercisable after the expiration of 10 years after
the date such option is granted, subject to earlier termination in the event
the optionee's service with Aastrom ceases or in the event of a Transfer of
Control of Aastrom, as discussed below. Initial Options and Annual Options
granted under the Directors Plan will become exercisable cumulatively in
installments of 8.33% of the shares subject to the option on the day preceding
each month occurring after the date of grant.

Generally, the exercise price may be paid in cash, by check, or in cash
equivalent, by tender of shares of Aastrom's common stock owned by the optionee
having a fair market value not less than the exercise price, by the assignment
of the proceeds of a sale or loan with respect to some or all of the shares of
common stock being acquired upon the exercise of the option, or by any
combination of these. During the lifetime of the optionee, the option may be
exercised only by the optionee. An option may not be transferred or assigned,
except by will or the laws of descent and distribution.

18
<PAGE>

Transfer of Control. The Directors Plan provides that, in the event of (i) a
sale or exchange by the shareholders in a single or series of related
transactions of more than 50% of Aastrom's voting stock, (ii) a merger or
consolidation in which Aastrom is a party, (iii) the sale, exchange or transfer
of all or substantially all of the assets of Aastrom, or (iv) a liquidation or
dissolution of Aastrom wherein, upon any such event, the shareholders of
Aastrom immediately before such event do not retain direct or indirect
beneficial ownership of more than 50% of the total combined voting power of the
voting stock of Aastrom, its successor, or the corporation to which the assets
of Aastrom were transferred (a Transfer of Control), all options outstanding
under the Directors Plan will become immediately exercisable and vested in full
prior to the Transfer of Control. In addition, the acquiring or successor
corporation may assume or substitute substantially equivalent options for the
options outstanding under the Directors Plan. To the extent that the options
outstanding under the Directors Plan are not assumed, substituted for, or
exercised prior to the Transfer of Control, they will terminate.

Termination or Amendment. The Directors Plan continues until terminated by
the Board or until all of the shares reserved for issuance under the plan have
been issued. The Board may terminate or amend the Directors Plan at any time.
However, subject to changes in the law that would permit otherwise, without
shareholder approval, the Board may not amend the Directors Plan to increase
the total number of shares of common stock reserved for issuance thereunder or
expand the class of persons eligible to receive options. The provisions of the
Directors Plan addressing eligibility to participate in the plan and the
amount, price and time of the grant of options may not be amended more than
once every six months, other than to comport to changes in the Code, the
Employee Retirement Income Security Act of 1974, or the rules thereunder. No
termination or amendment of the Directors Plan may adversely affect an
outstanding option without the consent of the optionee, unless such termination
or amendment is necessary to comply with any applicable law.

Summary of United States Federal Income Tax Consequences

The following summary is intended only as a general guide as to the United
States federal income tax consequences under current law of participation in
the Directors Plan and does not attempt to describe all possible federal or
other tax consequences of such participation or tax consequences based on
particular circumstances.

Options granted under the Directors Plan are nonstatutory stock options,
which have no special tax status. An optionee generally recognizes no taxable
income as the result of the grant of such an option. Upon exercise of a
nonstatutory stock option, the optionee normally recognizes ordinary income in
the amount of the difference between the option exercise price and the fair
market value of the shares on the exercise date. Upon the sale of stock
acquired by the exercise of a nonstatutory stock option, any gain or loss,
based on the difference between the sale price and the fair market value on the
exercise date, will be taxed as capital gain or loss. A capital gain or loss
will be long-term if the optionee's holding period of the shares is more 12
months. No tax deduction is available to Aastrom with respect to the grant of a
nonstatutory stock option or the sale of the stock acquired pursuant to such
grant. Aastrom generally should be entitled to a deduction equal to the amount
of ordinary income recognized by the optionee as a result of the exercise of a
nonstatutory stock option, except to the extent such deduction is limited by
applicable provisions of the Code or the regulations thereunder.

PROPOSAL 4

RATIFICATION OF APPOINTMENT OF
INDEPENDENT PUBLIC ACCOUNT

The Board of Directors of Aastrom has selected PricewaterhouseCoopers LLP as
its independent accountants to audit the financial statements of Aastrom for
the fiscal year ended June 30, 2001. PricewaterhouseCoopers LLP has acted in
such capacity since its appointment in July 1997.

19
<PAGE>

Abstentions will have the same effect as a negative vote. Broker non-votes will
have no effect on the outcome of the vote. The Board of Directors Unanimously
Recommends a Vote "FOR" the Appointment of PricewaterhouseCoopers, LLP as
Aastrom's Independent Accountants for the Fiscal Year Ending June 30, 2001.

SHAREHOLDER PROPOSALS TO BE PRESENTED
AT NEXT ANNUAL MEETING

Proposals of shareholders intended to be presented at the next Annual
Meeting of the Shareholders of Aastrom must be received by Aastrom at our
offices located at 24 Frank Lloyd Wright Drive, Ann Arbor, Michigan, 48105,
(other than proposals made under Rule 14a-8 of the Securities and Exchange Act
of 1934, as amended) by July 18, 2001.

TRANSACTION OF OTHER BUSINESS

At the date of this Proxy Statement, the only business which the Board of
Directors intends to present or knows that others will present at the meeting
is as set forth above. If any other matter or matters are properly brought
before the meeting, or any adjournment thereof, it is the intention of the
persons named in the accompanying form of proxy to vote the proxy on such
matters in accordance with their best judgment.

By Order of the Board of Directors

/s/ Todd E. Simpson
-------------------------------------
TODD E. SIMPSON
Secretary

October 3, 2000

20
<PAGE>

[LETTERHEAD OF AASTROM BIOSCIENCES INC]

October 3, 2000

Dear Shareholders:

2000 was an eventful year for Aastrom Biosciences, its employees, and you,
our shareholders. While the first half of the year presented some serious
challenges, the second half of the year has led us to a much improved position
with some exciting new opportunities. I want to take a moment to review the
events of the past year and to let you know how successful the Company has been
in rebounding from a very difficult period and positioning itself for
prosperity. It is important to note that without your support, we would not be
where we are today--improved financial stability, furthering U.S. development
of our platform product, poised to capitalize on the emerging dendritic cell
tumor vaccine boom, and having achieved several major milestones over the past
six months.

As you know, we began fiscal year 2000 by successfully moving our platform
product, the AastromReplicell(TM) System, from prototype to production-level
manufacturing and receiving CE Mark approval to begin sales in Europe. However,
as the Company prepared for the pilot-scale product launch in Europe, we were
met with a corresponding need for additional capital, which we were unable to
obtain at that time. This situation compelled the Company to announce
aggressive operational reductions. These actions included a reduction in work
force, a delay of clinical trial accruals and a suspension of the initial
European pilot launch of the AastromReplicell(TM) System.

This unfortunate circumstance was precipitated, in part, by negative
clinical results from independent studies that questioned the benefit of using
stem cell transplants to support high dose chemotherapy in breast cancer
patients, an indication which was being pursued as a lead market for the
AastromReplicell(TM) System and the SC-I Therapy Kit. As a result of the abrupt
changes in this medical treatment area and the negative financial market
conditions for the cell therapy sector, Aastrom was unable to obtain the
expected financing required for additional activities, such as the European
pilot launch.

Fortunately, breast cancer related stem cell transplants was only one of
several product and treatment indications that the Company has been pursuing.
Although this capability has not been widely understood, Aastrom is developing
products to enable the production of several types of human cells for the
treatment of a variety of medical disorders. Based on this position, and as
financial market conditions began to rebound, we were able to complete two
financings totaling $12 million, and we have begun to rebuild our operations.

Back on Track

In addition to obtaining new capital, there have been some important
developments that have lifted the Company to a new strategic position. A key
objective of our business strategy has been to expand the AastromReplicell(TM)
System product line to incorporate clinical indications beyond our initial
focus area of hematopoietic stem cell therapy. In order for this progress to
occur, successful demonstration of other cell-based therapeutic treatments was
imperative. This has recently come to fruition with the demonstration of
exciting progress in both the cancer immunotherapy and the bone repair fields.

In the March 2000 edition of the scientific journal, NATURE MEDICINE,
results from a multi-center clinical trial evaluating the use of ex-vivo
produced cells for immunotherapy treatment of cancer (also called "cancer
vaccines") were published. These results showed the remission of large tumors
in patients with renal cell cancer, and involved treating the patient with a
type of blood cell (dendritic cells) which triggers immune
<PAGE>

system action, all of which were produced and modified outside of the body ("ex
vivo"). This exciting new treatment procedure is currently being evaluated in
the treatment of other types of cancer, and there is evidence that similar
success will be achieved in these trials.

Although still at an early stage, this cell therapy procedure may become one
of the most important advances in cancer treatment, having the potential to
become a standard treatment method for several types of cancer. Particularly
exciting to Aastrom is that our products and technology are designed to enable
these current types of experimental laboratory processes to become
standardized, acceptable medical procedures. We believe that the Aastrom
capability is a critical component necessary in order for the procedures to
become more widely available to patients. The Company is currently developing a
new therapy kit, the DC-I Therapy Kit, that is designed to produce the
dendritic cells required for this procedure under automated process control. We
believe that as a medical device, the DC-I Therapy Kit provides a near-term
market opportunity, and will enable this important new therapeutic approach to
move into standard medical practice.

Our Bone Repair Program

Significant progress in our bone repair program was made this year when the
AastromReplicell(TM) System impacted a young girl's life. In response to a
"compassionate use" request, Aastrom participated in a novel clinical procedure
that would, if successful, enable a more normal life for a child suffering from
a crippling bone disorder. The patient needed a new source of normal bone cells
as her disease prevented her body from making normal healthy bone tissue. At
her physician's request, and with the FDA's permission, we provided the
AastromReplicell(TM) System to her physicians so they could produce bone
progenitor cells from a small bone marrow sample provided by her sister. The
AastromReplicell(TM) System produced an increased amount of bone progenitor
cells, which were then infused into the patient. This procedure appears to have
allowed her bones to gain density and, as a result, the child was subsequently
able to stand and walk without her bones crumbling.

This procedure, coupled with other positive pre-clinical research results,
allowed Aastrom and our partners at the University of Michigan to initiate a
formal Phase I/II clinical trial to officially evaluate the use of bone
progenitor cells produced in the OC-I Therapy Kit for the AastromReplicell(TM)
System in patients with severe osteoporosis. This trial is expected to be
initiated soon and we anticipate results from this trial in the second quarter
of 2001.

Looking Ahead

As we look ahead toward 2001, the potential markets for the
AastromReplicell(TM) System product line are significant. Clinical results
using the CB-I Therapy Kit were published in March, and demonstrated the
ability of this product to provide normal blood and immune systems in adult
leukemia patients. We estimate that more than 25,000 leukemia and genetic blood
disease patients annually are candidates for the CB-I Therapy Kit. The DC-I
Therapy Kit is being developed for the exciting new tumor vaccines as
treatments for renal cell cancer, melanoma, as well as other types of cancer.
Osteoporosis is also a potentially significant market, where current drug
treatments are principally used to slow progression of the disease. The OC-I
Therapy Kit is designed to produce bone progenitor cells that can form new bone
tissue.

With new funding in place and important new product areas under evaluation,
our management team has carefully revised our business strategy to include:

. Focusing on stem cell therapy activities in cord blood applications where
we believe we can uniquely enable the recovery of normal blood and immune
systems in leukemia patients. Aastrom's scientists also recently reported
a new approach to the production of the stem cell-containing fraction of
human cord blood, that increases their production by approximately ten-
fold above our previous capability (announced in May, 2000);

. Expanding the AastromReplicell(TM) System product line into new, non-stem
cell markets such as the dendritic cell tumor vaccines, and for the
treatment of degenerative bone diseases such as osteoporosis;
<PAGE>

. Identifying key strategic relationships that will assist in propelling
the AastromReplicell(TM) System into the European markets, and into new
therapeutic indications;

. Initiating collaborations with academic research organizations and
companies that are developing new cell therapies, and would benefit from
the enabling commercialization pathway provided by the
AastromReplicell(TM) System.

In addition to the above areas, we will also continue to expand the senior
leadership capability of the Company with addition of new members to the Board
of Directors and to the management team. The Company will also focus its
efforts on pursuing additional financial support, as well as continue to
explore strategic relationships for further support.

Now more than ever, cell therapy is moving to the forefront of landmark
therapeutic approaches, and Aastrom is now in the position to be a key player
in this new field. With the development of the AastromReplicell(TM) System
instrument platform completed, trials in stem cell therapy reinitiated, and
product development in the osteoporosis and tumor vaccine areas underway, your
Board of Directors, our employees and our management team look toward the
future with excitement and optimism.

Thank you for your interest and continued support of Aastrom. As we enter
the new year as a leader in products for cell therapy we can't help but
think--what a difference a year can make!

With Highest Regards,

/s/ R. Douglas Armstrong, Ph.D.
_____________________________________
R. Douglas Armstrong, Ph.D.
Chairman, Board of Directors Chief
Executive Officer and President

-------------------------------------------------------------------------------

This document contains forward-looking statements, including without
limitation statements concerning product development objectives, clinical
trial objectives, results and potential advantages of the Company's products,
and applications and commercialization of the AastromReplicell(TM) System,
which involve certain risks and uncertainties. The forward-looking statements
are also identified through use of the words "believes," "anticipates,"
"expects," "estimates," and other words of similar meaning. Actual results may
differ significantly from the expectations contained in the forward-looking
statements. Among the factors that may result in differences are the results
obtained from clinical trials and development activities, regulatory approval
requirements, sales and the availability of resources. These and other
significant factors are discussed in greater detail in Aastrom's Annual Report
on Form 10-K for the fiscal year ended June 30, 2000 and other filings with
the Securities and Exchange Commission.

<PAGE>

AASTROM BIOSCIENCES, INC.
Proxy for Annual Meeting of Shareholders
Solicited by the Board of Directors
The undersigned hereby appoints R. Douglas Armstrong and Todd E. Simpson, and
each of them, with full power of substitution to represent the undersigned and
to vote all of the shares of stock of Aastrom Biosciences, Inc. (the "Company")
which the undersigned is entitled to vote at the Annual Meeting of Shareholders
of the Company to be held at the Holiday Inn North Campus, Ann Arbor, Michigan
on Wednesday, November 15, 2000 at 9:00 a.m., and at any adjournment thereof
(i) as hereinafter specified upon the proposal listed on the reverse side and
as more particularly described in the Company's Proxy Statement, receipt of
which is hereby acknowledged, and (ii) in their discretion upon such other
matters as may properly come before the meeting.

The shares represented hereby shall be voted as specified. If no
specification is made, such shares shall be voted FOR proposal 1, proposal 2,
proposal 3 and proposal 4.

A vote FOR the following proposals is recommended by the Board of Directors:
1. ELECTION OF DIRECTORS.

Nominee: R. Douglas Armstrong [_] FOR [_] WITHHELD

Nominee: Joseph A. Taylor [_] FOR [_] WITHHELD

2. To approve an increase in the maximum aggregate number of shares that may
be issued under the Company's 1992 Incentive and Non-Qualified Stock
Option Plan from 3,300,000 shares to 4,700,000 shares.

[_] FOR [_] AGAINST [_] ABSTAIN

3. To approve (i) an increase in the maximum aggregate number of shares that
may be issued under the Company's 1996 Outside Directors Stock Option
Plan from 150,000 shares to 300,000 shares, and (ii) an increase in the
size of the initial option grant and the annual options granted from
5,000 shares to 10,000 shares.
[_] FOR [_] AGAINST [_] ABSTAIN

4. To approve the selection of PricewaterhouseCoopers LLP as the Company's
independent public accountants for the year ending June 30, 2001.

[_] FOR [_] AGAINST [_] ABSTAIN

CONTINUED AND TO BE SIGNED ON REVERSE SIDE

MARK HERE FOR ADDRESS CHANGE AND NOTE BELOW. [_]
Even if you are
planning to attend
the meeting in
person, you are
urged to sign and
mail the Proxy in
the return
envelope so that
your stock may be
represented at the
meeting.

Sign exactly as
your name(s)
appears on your
stock certificate.
If shares of stock
stand on record in
the names of two
or more persons or
in the name of
husband and wife,
whether as joint
tenants or
otherwise, both or
all of such
persons should
sign the above
Proxy. If shares
of stock are held
of record by a
corporation, the
Proxy should be
executed by the
President or Vice
President and the
Secretary or
Assistant
Secretary, and the
corporate seal
should be affixed
thereto. Executors
or administrators
or other
fiduciaries who
execute the above
Proxy for a
deceased
shareholder should
give their title.
Please date the
Proxy.

Signature(s) _______________________________ Date:_______________________